Please login to the form below

Not currently logged in

Biogen Idec names head of gene therapy

Olivier Danos joins from Kadmon Pharmaceuticals
Olivier Danos Biogen Idec

Biogen Idec has appointed Dr Olivier Danos as senior VP, gene therapy.

Dr Danos will lead Biogen Idec's gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering. Danos will also identify potential collaborations for the company.

“Olivier is a true pioneer in the field,” said Dr Douglas Williams, executive VP, R&D. “We believe that his expertise will help accelerate our development of a world-class gene therapy platform that combines our growing internal capabilities with collaborations with leading research organizations across the globe.”

Dr Danos joins Biogen Idec from Kadmon Pharmaceuticals, where he served as senior vice president, Molecular Medicine, Synthetic Biology and Gene Regulation since 2011.

Prior to Kadmon, Dr Danos acted as the director of the Gene Therapy Consortium of the University College of London and led a gene therapy research team at the Necker Hospital – Enfants Malades in Paris.

His career also includes a spell as president of the European Society of Gene and Cell Therapy.

24th September 2014

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

WCG is an independent, global agency specialising in healthcare communications. Our value as a company is about being the positive...

Latest intelligence

The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....
The Periodic Table of Healthcare Communications
The definitive framework for building healthcare communication strategies and plans. Covering Brand Planning, Customer Experience and Multi-channel Marketing....